1005: David Fajgenbaum | Leveraging AI to Cure Rare Diseases

AI Breakthroughs

David Fajgenbaum's journey began with his own battle against Castleman disease, a rare ailment with no effective treatment. He organized a global network of researchers and patients to create an international research agenda, aiming to find existing FDA-approved drugs that could treat the disease 1. The advent of AI has significantly accelerated this process, allowing his team to predict potential drug-disease matches across 66 million possibilities 2.

We can actually repeat the exact process that me and my lab have been doing, one disease at a time. But we can do it across all drugs and all diseases simultaneously.

--- David C. Fajgenbaum

This technological leap has enabled them to identify promising treatments more efficiently, offering new hope for patients with rare diseases.

   

Algorithm Development

The development of AI algorithms has been pivotal in finding new uses for existing drugs. David compares the process to Netflix's recommendation system, where the algorithm predicts potential drug-disease matches based on known successful treatments 3. This innovative approach has drastically reduced the time and labor involved in drug discovery.

It's like one big game of drug-related Where's Waldo? The cures are hiding in plain sight, but you gotta find the right one.

--- Jordan Harbinger

Federal funding has further bolstered these efforts, enabling the creation of a robust AI platform to match drugs to diseases more effectively than ever before 4.

   

Case Studies

AI has already shown remarkable success in identifying new treatments for rare diseases. In one instance, the algorithm identified a drug that saved a Castleman disease patient who had not responded to any other treatments 5. This breakthrough underscores the potential of AI in revolutionizing medical research.

Just because there's not a drug for your disease doesn't mean there's not a drug that can treat your disease.

--- David C. Fajgenbaum

Another success story involves a drug repurposed for angiosarcoma, a historically fatal cancer, which has now become a recommended treatment due to its life-saving results 6.